MARKET WIRE NEWS
  1. Home
  2. Stock
  3. REPL
  4. News
  5. Replimune Group The Prospects For Fda Approval After
REPL
Quote
Short
News
Articles
Message Board

Replimune Group: The Prospects For FDA Approval After Rejection

Source: SeekingAlpha

2025-08-07 10:08:04 ET

Topline Summary and Update

Read the full article on Seeking Alpha

For further details see:

Replimune Group: The Prospects For FDA Approval After Rejection
Replimune Group Inc.

NASDAQ: REPL

REPL Trading

-10.42% G/L:

$4.6493 Last:

4,448,331 Volume:

$5.06 Open:

mwn-link-x Ad 300

REPL Latest News

April 27, 2026 08:00:00 am
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2026 01:35:20 pm
TRT for Massive Gains
April 10, 2026 05:02:32 pm
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
March 02, 2026 08:00:00 am
Replimune to Present at Two Upcoming Investor Conferences

REPL Stock Data

$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
https://www.replimune.com
US
Woburn

Subscribe to Our Newsletter

Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.

Link Market Wire News to Your X Account

Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.

Download The Market Wire News App

Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.

Market Wire News iPhone App Market Wire News Android App